TY - JOUR AU - Friedlander, Philip PY - 2019 TI - The use of baseline tumor size to prognosticate overall survival in stage IV melanoma patients treated with the PD-1 inhibitor pembrolizumab JF - Annals of Translational Medicine; Vol 7, Supplement 1 (March 27, 2019): Annals of Translational Medicine Y2 - 2019 KW - N2 - Historically patients who developed stage IV melanoma were expected to live less than one year. Clinical outcome was heterogeneous as evidenced by a tail end to the overall survival (OS) curve which identifies a small subset of patients, encompassing less than 10% of the total population, who are long term survivors (1). UR - https://atm.amegroups.org/article/view/23763